{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:20:47Z","timestamp":1792268447787,"version":"4.4.0"},"reference-count":202,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T00:00:00Z","timestamp":1642896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s00223-021-00933-1","type":"journal-article","created":{"date-parts":[[2022,1,23]],"date-time":"2022-01-23T04:02:26Z","timestamp":1642910546000},"page":"393-420","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Bone Involvement in Patients with Spondyloarthropathies"],"prefix":"10.1007","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6885-3953","authenticated-orcid":false,"given":"Willem","family":"Lems","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinne","family":"Miceli-Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Haschka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Giusti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gitte Lund","family":"Chistensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kocijan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Rosine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niklas Rye","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerolamo","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Roux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,23]]},"reference":[{"issue":"2","key":"933_CR1","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/ar2642","volume":"11","author":"RJ Lories","year":"2009","unstructured":"Lories RJ, Luyten FP, de Vlam K (2009) Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther 11(2):221","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"933_CR2","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D et al (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheumatol 58(10):3063\u20133070","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"933_CR3","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheumatol 58(5):1324\u20131331","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"933_CR4","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/art.21133","volume":"52","author":"D van der Heijde","year":"2005","unstructured":"van der Heijde D, Landew\u00e9 R, van der Linden S (2005) How should treatment effect on spinal radiographic progression in patients with ankylosing spondylitis be measured? Arthritis Rheumatol 52(7):1979\u20131985","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"933_CR5","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N et al (2013) The Impact of TNF-inhibitors on radiographic progression in Ankylosing Spondylitis. Arthritis Rheumtol 65(10):2645\u20132654","journal-title":"Arthritis Rheumtol"},{"issue":"1","key":"933_CR6","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","volume":"74","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F, Landew\u00e9 R (2015 Jan) Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 74(1):52\u201359","journal-title":"Ann Rheum Dis"},{"key":"933_CR7","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1002\/art.33453","volume":"64","author":"Y Gong","year":"2012","unstructured":"Gong Y, Zheng N, Chen SB et al (2012) Ten years\u2019 experience with needle biopsy in the early diagnosis of sacroiliitis. Arthritis Rheumatol 64:1399\u20131406","journal-title":"Arthritis Rheumatol"},{"key":"933_CR8","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1136\/annrheumdis-2013-203425","volume":"73","author":"X Baraliakos","year":"2014","unstructured":"Baraliakos X et al (2014) A long-term observational study using MRI and conventional radiography. Ann Rheum Dis 73:1819\u20131825. https:\/\/doi.org\/10.1136\/annrheumdis-2013-203425","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"933_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.berh.2010.01.005","volume":"24","author":"G Schett","year":"2010","unstructured":"Schett G, Rudwaleit M (2010) Can we stop progression of ankylosing spondylitis? Best Pract Res Clin Rheumatol 24(3):363\u2013371. https:\/\/doi.org\/10.1016\/j.berh.2010.01.005","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"933_CR10","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1136\/ard.2006.066415","volume":"66","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Rudwaleit M et al (2007) Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 66:910\u2013915","journal-title":"Ann Rheum Dis"},{"key":"933_CR11","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1002\/art.33465","volume":"64","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Haibel H, Listing J et al (2012) Baseline radiographic damage, elevated acute phase reactant levels, and cigarette smoking status predict spinal radiographic progression in early axial spondylarthritis. Arthritis Rheumatol 64:1388\u20131398","journal-title":"Arthritis Rheumatol"},{"key":"933_CR12","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1136\/annrheumdis-2015-208011","volume":"75","author":"PM Machado","year":"2016","unstructured":"Machado PM, Baraliakos X, van der Heijde D, Braun J, Landew\u00e9 R (2016) MRI vertebral corner inflammation followed by fat deposition is the strongest contributor to the development of new bone at the same vertebral corner: a multilevel longitudinal analysis in patients with ankylosing spondylitis. Ann Rheum Dis 75:1486\u20131493","journal-title":"Ann Rheum Dis"},{"key":"933_CR13","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.38775","volume":"66","author":"S Ramiro","year":"2014","unstructured":"Ramiro S, van Tubergen A, van der Heijde D et al (2014) Brief report\u202f: erosions and sclerosis on radiographs precede the subsequent development of syndesmophytes at the same site: a twelve-year prospective follow-up of patients with ankylosing spondylitis. Arthritis Rheumatol 66:2773\u20132779","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"933_CR14","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/art.24585","volume":"61","author":"MM Ward","year":"2009","unstructured":"Ward MM, Hendrey MR, Malley JD, Learch TJ, Davis JC Jr, Reveille JD, Weisman MH (2009) Clinical and immunogenetic prognostic factors for radiographic severity in ankylosing spondylitis. Arthritis Rheumatol 61(7):859\u2013866","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"933_CR15","doi-asserted-by":"crossref","first-page":"e000153","DOI":"10.1136\/rmdopen-2015-000153","volume":"1","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Landew\u00e9 R, van Tubergen A, Boonen A, Stolwijk C, Dougados M, van den Bosch F, van der Heijde D (2015) Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis. RMD Open 1(1):e000153","journal-title":"RMD Open"},{"issue":"1","key":"933_CR16","doi-asserted-by":"crossref","first-page":"e001480","DOI":"10.1136\/rmdopen-2020-001480","volume":"7","author":"FM Perrotta","year":"2021","unstructured":"Perrotta FM, Lories R, Lubrano E (2021) To move or not to move: the paradoxical effect of physical exercise in axial spondyloarthritis. RMD Open 7(1):e001480","journal-title":"RMD Open"},{"issue":"6","key":"933_CR17","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/1529-0131(200106)44:6<1396::AID-ART233>3.0.CO;2-A","volume":"44","author":"J Hamersma","year":"2001","unstructured":"Hamersma J, Cardon LR, Bradbury L, Brophy S, van der Horst-Bruinsma I, Calin A, Brown MA (2001) Is disease severity in ankylosing spondylitis genetically determined? Arthritis Rheumatol 44(6):1396\u20131400","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"933_CR18","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1002\/art.33430","volume":"64","author":"N Haroon","year":"2012","unstructured":"Haroon N, Maksymowych WP, Rahman P, Tsui FW, O\u2019Shea FD, Inman RD (2012) Radiographic severity of ankylosing spondylitis is associated with polymorphism of the large multifunctional peptidase 2 gene in the Spondyloarthritis Research Consortium of Canada cohort. Arthritis Rheumatol 64(4):1119\u20131126","journal-title":"Arthritis Rheumatol"},{"issue":"8","key":"933_CR19","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1093\/rheumatology\/kes056","volume":"51","author":"N Bartolom\u00e9","year":"2012","unstructured":"Bartolom\u00e9 N, Szczypiorska M, S\u00e1nchez A, Sanz J, Juanola-Roura X, Gratac\u00f3s J, Zarco-Montejo P, Collantes E, Mart\u00ednez A, Tejedor D, Artieda M, Mulero J (2012) Genetic polymorphisms inside and outside the MHC improve prediction of AS radiographic severity in addition to clinical variables. Rheumatology (Oxford) 51(8):1471\u20131478","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"933_CR20","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/annrheumdis-2013-204835","volume":"74","author":"A Cortes","year":"2015","unstructured":"Cortes A, Maksymowych WP, Wordsworth BP, Inman RD, Danoy P, Rahman P, Stone MA, Corr M, Gensler LS, Gladman D, Morgan A, Marzo-Ortega H, Ward MM, SPARCC (Spondyloarthritis Research Consortium of Canada), TASC (Australo-Anglo-American Spondyloarthritis Consortium), Learch TJ, Reveille JD, Brown MA, Weisman MH (2015) Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. Ann Rheum Dis 74(7):1387\u20131393","journal-title":"Ann Rheum Dis"},{"key":"933_CR21","first-page":"213328","volume":"2018","author":"D Baeten","year":"2018","unstructured":"Baeten D, \u00d8stergaard M, Wei JC-C, Sieper J, J\u00e4rvinen P, Tam L-S et al (2018) Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 2018:213328","journal-title":"Ann Rheum Dis"},{"issue":"26","key":"933_CR22","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","volume":"373","author":"D Baeten","year":"2015","unstructured":"Baeten D, Sieper J, Braun J, Baraliakos X, Dougados M, Emery P et al (2015) Secukinumab, an interleukin-17A inhibitor ankylosing spondylitis. N Engl J Med 373(26):2534\u20132548","journal-title":"N Engl J Med"},{"issue":"6","key":"933_CR23","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A, Baeten D, Sieper J, Emery P et al (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76(6):1070\u20131077","journal-title":"Ann Rheum Dis"},{"issue":"10217","key":"933_CR24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(19)32971-X","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, van der Heijde D, Gensler LS, Kim TH, Maksymowych WP, \u00d8stergaard M, Poddubnyy D, Marzo-Ortega H, Bessette L, Tomita T, Leung A, Hojnik M, Gallo G, Li X, Adams D, Carlier H, Sieper J (2020) Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial. Lancet 395(10217):53\u201364","journal-title":"Lancet"},{"issue":"2","key":"933_CR25","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1136\/annrheumdis-2019-216118","volume":"79","author":"M Dougados","year":"2020","unstructured":"Dougados M, Wei JC, Landew\u00e9 R, Sieper J, Baraliakos X, Van den Bosch F, Maksymowych WP, Ermann J, Walsh JA, Tomita T, Deodhar A, van der Heijde D, Li X, Zhao F, Bertram CC, Gallo G, Carlier H, Gensler LS (2020) Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W). Ann Rheum Dis 79(2):176\u2013185","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"933_CR26","doi-asserted-by":"crossref","first-page":"7731","DOI":"10.1038\/s41598-018-25722-z","volume":"8","author":"N Rosine","year":"2018","unstructured":"Rosine N, Etcheto A, Hendel-Chavez H, Seror R, Briot K, Molto A, Chanson P, Taoufik Y, Wendling D, Lories R, Berenbaum F, van den Berg R, Claudepierre P, Feydy A, Dougados M, Roux C, Miceli-Richard C (2018 May 16) Increase In Il-31 serum levels is associated with reduced structural damage in early axial spondyloarthritis. Sci Rep 8(1):7731","journal-title":"Sci Rep"},{"issue":"3","key":"933_CR27","doi-asserted-by":"crossref","first-page":"R95","DOI":"10.1186\/ar3370","volume":"13","author":"H Appel","year":"2011","unstructured":"Appel H, Maier R, Wu P, Scheer R, Hempfing A, Kayser R et al (2011) Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response. Arthritis Res Ther 13(3):R95","journal-title":"Arthritis Res Ther"},{"issue":"8","key":"933_CR28","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/annrheumdis-2020-217309","volume":"79","author":"A Watad","year":"2020","unstructured":"Watad A, Rowe H, Russell T, Zhou Q, Anderson LK, Khan A et al (2020) Normal human enthesis harbours conventional CD4+ and CD8+ T cells with regulatory features and inducible IL-17A and TNF expression. Ann Rheum Dis 79(8):1044\u20131054","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"933_CR29","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1002\/art.40150","volume":"69","author":"RJ Cuthbert","year":"2017","unstructured":"Cuthbert RJ, Fragkakis EM, Dunsmuir R, Li Z, Coles M, Marzo-Ortega H et al (2017) Brief report: group 3 innate lymphoid cells in human enthesis. Arthritis Rheumatol 69(9):1816\u20131822","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"933_CR30","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","volume":"78","author":"RJ Cuthbert","year":"2019","unstructured":"Cuthbert RJ, Watad A, Fragkakis EM, Dunsmuir R, Loughenbury P, Khan A et al (2019) Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis 78(11):1559\u20131565","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"933_CR31","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1002\/art.39282","volume":"67","author":"E Vieira-Sousa","year":"2015","unstructured":"Vieira-Sousa E, van Duivenvoorde LM, Fonseca JE, Lories RJ, Baeten DL (2015) Review: animal models as a tool to dissect pivotal pathways driving spondyloarthritis. Arthritis Rheumatol 67(11):2813\u20132827","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"933_CR32","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1002\/art.34423","volume":"64","author":"M Ruutu","year":"2012","unstructured":"Ruutu M, Thomas G, Steck R, Degli-Esposti MA, Zinkernagel MS, Alexander K et al (2012) \u03b2-glucan triggers spondylarthritis and Crohn\u2019s disease-like ileitis in SKG mice. Arthritis Rheumatol 64(7):2211\u20132222","journal-title":"Arthritis Rheumatol"},{"key":"933_CR33","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3389\/fimmu.2018.01550","volume":"9","author":"MN van Tok","year":"2018","unstructured":"van Tok MN, Na S, Lao CR, Alvi M, Pots D, van de Sande MGH et al (2018) The initiation, but not the persistence, of experimental spondyloarthritis is dependent on interleukin-23 signaling. Front Immunol 9:1550","journal-title":"Front Immunol"},{"issue":"7","key":"933_CR34","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M, Grein J et al (2012) IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med 18(7):1069\u20131076","journal-title":"Nat Med"},{"issue":"10","key":"933_CR35","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","volume":"68","author":"A Reinhardt","year":"2016","unstructured":"Reinhardt A, Yevsa T, Worbs T, Lienenklaus S, Sandrock I, Oberd\u00f6rfer L et al (2016) Interleukin-23-dependent \u03b3\/\u03b4 T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol 68(10):2476\u20132486","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"933_CR36","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/art.40770","volume":"71","author":"MN van Tok","year":"2019","unstructured":"van Tok MN, van Duivenvoorde LM, Kramer I, Ingold P, Pfister S, Roth L et al (2019) Interleukin-17A inhibition diminishes inflammation and new bone formation in experimental spondyloarthritis. Arthritis Rheumatol 71(4):612\u2013625","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"933_CR37","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.bbrc.2011.12.106","volume":"417","author":"T Asari","year":"2012","unstructured":"Asari T, Furukawa K-I, Tanaka S, Kudo H, Mizukami H, Ono A et al (2012) Mesenchymal stem cell isolation and characterization from human spinal ligaments. Biochem Biophys Res Commun 417(4):1193\u20131199","journal-title":"Biochem Biophys Res Commun"},{"issue":"10","key":"933_CR38","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1038\/cdd.2009.74","volume":"16","author":"H Huang","year":"2009","unstructured":"Huang H, Kim HJ, Chang EJ, Lee ZH, Hwang SJ, Kim HM, Lee Y, Kim HH (2009 Oct) IL-17 stimulates the proliferation and differentiation of human mesenchymal stem cells: implications for bone remodeling. Cell Death Differ 16(10):1332\u20131343","journal-title":"Cell Death Differ"},{"issue":"6","key":"933_CR39","doi-asserted-by":"crossref","first-page":"e40044","DOI":"10.1371\/journal.pone.0040044","volume":"7","author":"D Nam","year":"2012","unstructured":"Nam D, Mau E, Wang Y, Wright D, Silkstone D, Whetstone H et al (2012) T-lymphocytes enable osteoblast maturation via IL-17F during the early phase of fracture repair. PLoS ONE 7(6):e40044","journal-title":"PLoS ONE"},{"key":"933_CR40","first-page":"425","volume":"5","author":"B Osta","year":"2014","unstructured":"Osta B, Lavocat F, Eljaafari A, Miossec P (2014) Effects of interleukin-17A on osteogenic differentiation of isolated human mesenchymal stem cells. Front Immunol 5:425","journal-title":"Front Immunol"},{"issue":"1","key":"933_CR41","doi-asserted-by":"crossref","first-page":"7269","DOI":"10.1038\/s41598-018-25564-9","volume":"8","author":"M Croes","year":"2018","unstructured":"Croes M, Kruyt MC, Groen WM, van Dorenmalen KMA, Dhert WJA, \u00d6ner FC et al (2018) Interleukin 17 enhances bone morphogenetic protein-2-induced ectopic bone formation. Sci Rep 8(1):7269","journal-title":"Sci Rep"},{"issue":"4","key":"933_CR42","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1002\/eji.201141786","volume":"42","author":"A Riegel","year":"2012","unstructured":"Riegel A, Maurer T, Prior B, Stegmaier S, Heppert V, Wagner C et al (2012) Human polymorphonuclear neutrophils express RANK and are activated by its ligand. RANKL. Eur J Immunol. 42(4):975\u2013981","journal-title":"RANKL. Eur J Immunol."},{"issue":"12","key":"933_CR43","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1056\/NEJMoa1612197","volume":"376","author":"NM Moutsopoulos","year":"2017","unstructured":"Moutsopoulos NM, Zerbe CS, Wild T, Dutzan N, Brenchley L, DiPasquale G et al (2017) Interleukin-12 and interleukin-23 blockade in leukocyte adhesion deficiency type 1. N Engl J Med 376(12):1141\u20131146","journal-title":"N Engl J Med"},{"issue":"229","key":"933_CR44","doi-asserted-by":"crossref","first-page":"229ra40","DOI":"10.1126\/scitranslmed.3007696","volume":"6","author":"NM Moutsopoulos","year":"2014","unstructured":"Moutsopoulos NM, Konkel J, Sarmadi M, Eskan MA, Wild T, Dutzan N et al (2014) Defective neutrophil recruitment in leukocyte adhesion deficiency type I disease causes local IL-17-driven inflammatory bone loss. Sci Transl Med. 6(229):229ra40","journal-title":"Sci Transl Med."},{"key":"933_CR45","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/eji.202048878","volume":"51","author":"C Papagoras","year":"2021","unstructured":"Papagoras C, Chrysanthopoulou A, Mitsios A, Ntinopoulou M, Tsironidou V, Batsali AK et al (2021) IL 17A expressed on neutrophil extracellular traps promotes mesenchymal stem cell differentiation towards bone-forming cells in ankylosing spondylitis. Eur J Immunol 51:930","journal-title":"Eur J Immunol"},{"issue":"1","key":"933_CR46","first-page":"133","volume":"37","author":"A Fassio","year":"2019","unstructured":"Fassio A, Gatti D, Rossini M, Idolazzi L, Giollo A, Adami G et al (2019) Secukinumab produces a quick increase in WNT signalling antagonists in patients with psoriatic arthritis. Clin Exp Rheumatol f\u00e9vr 37(1):133\u2013136","journal-title":"Clin Exp Rheumatol f\u00e9vr"},{"key":"933_CR47","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/ni.1698","volume":"10","author":"MJ McGeachy","year":"2009","unstructured":"McGeachy MJ, Chen Y, Tato CM, Laurence A, Joyce-Shaikh B, Blumenschein WM, McClanahan TK, O\u2019Shea JJ, Cua DJ (2009) The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo. Nat Immunol 10:314\u2013324","journal-title":"Nat Immunol"},{"issue":"9","key":"933_CR48","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1136\/annrheumdis-2018-213328","volume":"77","author":"D Baeten","year":"2018","unstructured":"Baeten D, \u00d8stergaard M, Wei JC, Sieper J, J\u00e4rvinen P, Tam LS, Salvarani C, Kim TH, Solinger A, Datsenko Y, Pamulapati C, Visvanathan S, Hall DB, Aslanyan S, Scholl P, Padula SJ (2018 Sep) Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann Rheum Dis 77(9):1295\u20131302","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"933_CR49","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","volume":"71","author":"A Deodhar","year":"2019","unstructured":"Deodhar A, Gensler LS, Sieper J, Clark M, Calderon C, Wang Y, Zhou Y, Leu JH, Campbell K, Sweet K, Harrison DD, Hsia EC, van der Heijde D (2019) Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol 71(2):258\u2013270","journal-title":"Arthritis Rheumatol"},{"key":"933_CR50","unstructured":"Ritchlin C, Rahman P, Kavanaugh A, McInnes IB, Puig L, Li S, Wang Y, Shen YK, Doyle MK, Mendelsohn AM, Gottlieb AB, PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial."},{"issue":"9894","key":"933_CR51","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","volume":"382","author":"IB McInnes","year":"2013","unstructured":"McInnes IB, Kavanaugh A, Gottlieb AB, Puig L, Rahman P, Ritchlin C, Brodmerkel C, Li S, Wang Y, Mendelsohn AM, Doyle MK (2013) Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382(9894):780\u2013789","journal-title":"Lancet"},{"issue":"10","key":"933_CR52","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1002\/art.39732","volume":"68","author":"A Reinhardt","year":"2016","unstructured":"Reinhardt A, Yevsa T, Worbs T, Lienenklaus S, Sandrock I, Oberd\u00f6rfer L, Korn T, Weiss S, F\u00f6rster R, Prinz I (2016 Oct) Interleukin-23-dependent \u03b3\/\u03b4 T cells produce interleukin-17 and accumulate in the enthesis, aortic valve, and ciliary body in mice. Arthritis Rheumatol 68(10):2476\u20132486","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"933_CR53","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1136\/annrheumdis-2019-215210","volume":"78","author":"RJ Cuthbert","year":"2019","unstructured":"Cuthbert RJ, Watad A, Fragkakis EM, Dunsmuir R, Loughenbury P, Khan A, Millner PA, Davison A, Marzo-Ortega H, Newton D, Bridgewood C, McGonagle DG (2019 Nov) Evidence that tissue resident human enthesis \u03b3\u03b4T-cells can produce IL-17A independently of IL-23R transcript expression. Ann Rheum Dis 78(11):1559\u20131565","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"933_CR54","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1136\/annrheumdis-2015-208902","volume":"75","author":"E Gracey","year":"2016","unstructured":"Gracey E, Qaiyum Z, Almaghlouth I, Lawson D, Karki S, Avvaru N, Zhang Z, Yao Y, Ranganathan V, Baglaenko Y, Inman RD (2016 Dec) IL-7 primes IL-17 in mucosal-associated invariant T (MAIT) cells, which contribute to the Th17-axis in ankylosing spondylitis. Ann Rheum Dis 75(12):2124\u20132132","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"933_CR55","doi-asserted-by":"crossref","first-page":"e001306","DOI":"10.1136\/rmdopen-2020-001306","volume":"6","author":"M Shah","year":"2020","unstructured":"Shah M, Maroof A, Gikas P, Mittal G, Keen R, Baeten D et al (2020) Dual neutralisation of IL-17F and IL-17A with bimekizumab blocks inflammation-driven osteogenic differentiation of human periosteal cells. RMD Open 6(2):e001306","journal-title":"RMD Open"},{"key":"933_CR56","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1136\/annrheumdis-2011-200216","volume":"71","author":"GR Heiland","year":"2012","unstructured":"Heiland GR, Appel H, Poddubnyy D et al (2012) High level of functional dickkopf-1 predicts protection from syndesmophyte formation in patients with ankylosing spondylitis. Ann Rheum Dis 71:572\u2013574","journal-title":"Ann Rheum Dis"},{"key":"933_CR57","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K et al (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156\u2013163","journal-title":"Nat Med"},{"key":"933_CR58","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1136\/ard.2008.102046","volume":"69","author":"S Uderhardt","year":"2010","unstructured":"Uderhardt S, Diarra D, Katzenbeisser J, David JP, Zwerina J, Richards W, Kronke G, Schett G (2010) Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann Rheum Dis 69:592\u2013597","journal-title":"Ann Rheum Dis"},{"key":"933_CR59","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/03009742.2016.1152399","volume":"45","author":"JI Gamez-Nava","year":"2016","unstructured":"Gamez-Nava JI, de la Cerda-Trujillo LF, Vazquez-Villegas ML et al (2016) Association between bone turnover markers, clinical variables, spinal syndesmophytes and bone mineral density in Mexican patients with ankylosing spondylitis. Scand J Rheumatol 45:480\u2013490","journal-title":"Scand J Rheumatol"},{"key":"933_CR60","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1007\/s00198-010-1338-7","volume":"22","author":"S Arends","year":"2011","unstructured":"Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, Brouwer E, van der Veer E (2011) The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 22:1431\u20131439","journal-title":"Osteoporos Int"},{"key":"933_CR61","doi-asserted-by":"crossref","first-page":"e99685","DOI":"10.1371\/journal.pone.0099685","volume":"9","author":"S Arends","year":"2014","unstructured":"Arends S, Spoorenberg A, Efde M, Bos R, Leijsma MK, Bootsma H, Veeger NJ, Brouwer E, van der Veer E (2014) Higher bone turnover is related to spinal radiographic damage and low bone mineral density in ankylosing spondylitis patients with active disease: a cross-sectional analysis. PLoS ONE 9:e99685","journal-title":"PLoS ONE"},{"key":"933_CR62","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1136\/ard.2007.075085","volume":"67","author":"E Toussirot","year":"2008","unstructured":"Toussirot E, Dumoulin G, Saas P, Nguyen NU, Le Hu\u00e9d\u00e9 G, Wendling D (2008) Increased tartrate-resistant acid phosphatase serum levels in ankylosing spondylitis and relationship with the inflammatory process. Ann Rheum Dis 67:430\u2013431","journal-title":"Ann Rheum Dis"},{"key":"933_CR63","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s00223-015-0001-x","volume":"97","author":"L Wang","year":"2015","unstructured":"Wang L, Gao L, Jin D, Wang P, Yang B, Deng W, Xie Z, Tang Y, Wu Y, Shen H (2015) The relationship of bone mineral density to oxidant\/antioxidant status and inflammatory and bone turnover markers in a multicenter cross-sectional study of young men with ankylosing spondylitis. Calcif Tissue Int 97:12\u201322","journal-title":"Calcif Tissue Int"},{"key":"933_CR64","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00124743-200110000-00011","volume":"7","author":"P Borman","year":"2001","unstructured":"Borman P, Bodur H, Bing\u00f6l N, Bing\u00f6l S, Bostan EE (2001) Bone mineral density and bone turnover markers in a group of male ankylosing spondylitis patients: relationship to disease activity. J Clin Rheumatol 7:315\u2013321","journal-title":"J Clin Rheumatol"},{"key":"933_CR65","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3349\/ymj.2008.49.2.288","volume":"49","author":"MC Park","year":"2008","unstructured":"Park MC, Chung SJ, Park YB, Lee SK (2008) Bone and cartilage turnover markers, bone mineral density, and radiographic damage in men with ankylosing spondylitis. Yonsei Med J 49:288\u2013294","journal-title":"Yonsei Med J"},{"key":"933_CR66","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/BOR.0000000000000053","volume":"26","author":"S Arends","year":"2014","unstructured":"Arends S, Spoorenberg A, Brouwer E, van der Veer E (2014) Clinical studies on bone-related outcome and the effect of TNF-\u03b1 blocking therapy in ankylosing spondylitis. Curr Opin Rheumatol 26:259\u2013268","journal-title":"Curr Opin Rheumatol"},{"key":"933_CR67","doi-asserted-by":"crossref","first-page":"R98","DOI":"10.1186\/ar3823","volume":"14","author":"S Arends","year":"2012","unstructured":"Arends S, Spoorenberg A, Houtman PM, Leijsma MK, Bos R, Kallenberg CG, Groen H, Brouwer E, van der Veer E (2012) The effect of three years of TNF\u03b1 blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 14:R98","journal-title":"Arthritis Res Ther"},{"key":"933_CR68","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.3899\/jrheum.150019","volume":"42","author":"H Li","year":"2015","unstructured":"Li H, Li Q, Chen X, Ji C, Gu J (2015) Anti-tumor necrosis factor therapy increased spine and femoral neck bone mineral density of patients with active ankylosing spondylitis with low bone mineral density. J Rheumatol 42:1413\u20131417","journal-title":"J Rheumatol"},{"key":"933_CR69","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/ard.2007.076711","volume":"67","author":"M Gengenbacher","year":"2008","unstructured":"Gengenbacher M, Sebald HJ, Villiger PM, Hofstetter W, Seitz M (2008) Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. Ann Rheum Dis 67:620\u2013624","journal-title":"Ann Rheum Dis"},{"key":"933_CR70","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/ard.2007.084426","volume":"68","author":"S Visvanathan","year":"2009","unstructured":"Visvanathan S, van der Heijde D, Deodhar A, Wagner C, Baker DG, Han J, Braun J (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68:175\u2013182","journal-title":"Ann Rheum Dis"},{"key":"933_CR71","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1093\/rheumatology\/ken385","volume":"47","author":"ST Choi","year":"2008","unstructured":"Choi ST, Kim JH, Kang EJ, Lee SW, Park MC, Park YB, Lee SK (2008) Osteopontin might be involved in bone remodelling rather than in inflammation in ankylosing spondylitis. Rheumatology (Oxford) 47:1775\u20131779","journal-title":"Rheumatology (Oxford)"},{"key":"933_CR72","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3899\/jrheum.150857","volume":"43","author":"MA van der Weijden","year":"2016","unstructured":"van der Weijden MA, van Denderen JC, Lems WF, Nurmohamed MT, Dijkmans BA, van der Horst-Bruinsma IE (2016) Etanercept increases bone mineral density in ankylosing spondylitis, but does not prevent vertebral fractures: results of a prospective observational cohort study. J Rheumatol 43:758\u2013764","journal-title":"J Rheumatol"},{"key":"933_CR73","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/01.rhu.0000255688.83037.42","volume":"13","author":"S Sarikaya","year":"2007","unstructured":"Sarikaya S, Basaran A, Tekin Y, Ozdolap S, Ortancil O (2007) Is osteoporosis generalized or localized to central skeleton in ankylosing spondylitis? J Clin Rheumatol 13:20\u201324","journal-title":"J Clin Rheumatol"},{"key":"933_CR74","first-page":"2201","volume":"26","author":"D Mitra","year":"1999","unstructured":"Mitra D, Elvins DM, Collins AJ (1999) Biochemical markers of bone metabolism in mild ankylosing spondylitis and their relationship with bone mineral density and vertebral fractures. J Rheumatol 26:2201\u20132204","journal-title":"J Rheumatol"},{"key":"933_CR75","first-page":"516","volume":"29","author":"DJ Speden","year":"2002","unstructured":"Speden DJ, Calin AI, Ring FJ, Bhalla AK (2002) Bone mineral density, calcaneal ultrasound, and bone turnover markers in women with ankylosing spondylitis. J Rheumatol 29:516\u2013521","journal-title":"J Rheumatol"},{"key":"933_CR76","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/ard.52.5.343","volume":"52","author":"H Franck","year":"1993","unstructured":"Franck H, Keck E (1993) Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 52:343\u2013346","journal-title":"Ann Rheum Dis"},{"key":"933_CR77","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5606\/ArchRheumatol.2016.5857","volume":"31","author":"J Huang","year":"2016","unstructured":"Huang J, Song G, Yin Z, Fu Z, Ye Z (2016) Alteration of bone turnover markers in canonical wingless pathway in patients with ankylosing spondylitis. Arch Rheumatol 31:221\u2013228","journal-title":"Arch Rheumatol"},{"key":"933_CR78","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s00296-011-2237-8","volume":"32","author":"AC Bay-Jensen","year":"2012","unstructured":"Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA (2012) Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int 32:3565\u20133572","journal-title":"Rheumatol Int"},{"key":"933_CR79","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1007\/s00296-011-1981-0","volume":"32","author":"SR Kwon","year":"2012","unstructured":"Kwon SR, Lim MJ, Suh CH, Park SG, Hong YS, Yoon BY, Kim HA, Choi HJ, Park W (2012) Dickkopf-1 level is lower in patients with ankylosing spondylitis than in healthy people and is not influenced by anti-tumor necrosis factor therapy. Rheumatol Int 32:2523\u20132527","journal-title":"Rheumatol Int"},{"key":"933_CR80","first-page":"2236","volume":"31","author":"H Franck","year":"2004","unstructured":"Franck H, Meurer T, Hofbauer LC (2004) Evaluation of bone mineral density, hormones, biochemical markers of bone metabolism, and osteoprotegerin serum levels in patients with ankylosing spondylitis. J Rheumatol 31:2236\u20132241","journal-title":"J Rheumatol"},{"key":"933_CR81","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.3899\/jrheum.131199","volume":"41","author":"E Klingberg","year":"2014","unstructured":"Klingberg E, Nurkkala M, Carlsten H, Forsblad-d\u2019Elia H (2014) Biomarkers of bone metabolism in ankylosing spondylitis in relation to osteoproliferation and osteoporosis. J Rheumatol 41:1349\u20131356","journal-title":"J Rheumatol"},{"key":"933_CR82","doi-asserted-by":"crossref","first-page":"688","DOI":"10.6061\/clinics\/2014(10)07","volume":"69","author":"T Tuylu","year":"2014","unstructured":"Tuylu T, Sari I, Solmaz D, Kozaci DL, Akar S, Gunay N, Onen F, Akkoc N (2014) Fetuin-A is related to syndesmophytes in patients with ankylosing spondylitis: a case control study. Clinics (Sao Paulo, Brazil) 69:688\u2013693","journal-title":"Clinics (Sao Paulo, Brazil)"},{"key":"933_CR83","doi-asserted-by":"crossref","first-page":"0134974","DOI":"10.1371\/journal.pone.0134974","volume":"10","author":"G Nocturne","year":"2015","unstructured":"Nocturne G, Pavy S, Boudaoud S et al (2015) Increase in Dickkopf-1 serum level in recent spondyloarthritis. Data from the DESIR cohort. PLoS ONE 10:0134974","journal-title":"PLoS ONE"},{"key":"933_CR84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/1471-2474-14-99","volume":"14","author":"M Korkosz","year":"2013","unstructured":"Korkosz M, G\u0105sowski J, Leszczy\u0144ski P, Pawlak-Bu\u015b K, Jeka S, Kucharska E, Grodzicki T (2013) High disease activity in ankylosing spondylitis is associated with increased serum sclerostin level and decreased wingless protein-3a signaling but is not linked with greater structural damage. BMC Musculoskelet Disord 14:99","journal-title":"BMC Musculoskelet Disord"},{"key":"933_CR85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1471-2474-13-191","volume":"13","author":"A Taylan","year":"2012","unstructured":"Taylan A, Sari I, Akinci B, Bilge S, Kozaci D, Akar S, Colak A, Yalcin H, Gunay N, Akkoc N (2012) Biomarkers and cytokines of bone turnover: extensive evaluation in a cohort of patients with ankylosing spondylitis. BMC Musculoskelet Disord 13:191","journal-title":"BMC Musculoskelet Disord"},{"key":"933_CR86","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s00223-015-0093-3","volume":"98","author":"M Rossini","year":"2016","unstructured":"Rossini M, Viapiana O, Idolazzi L, Ghellere F, Fracassi E, Troplini S, Povino MR, Kunnathully V, Adami S, Gatti D (2016) Higher level of Dickkopf-1 is associated with low bone mineral density and higher prevalence of vertebral fractures in patients with ankylosing spondylitis. Calcif Tissue Int 98:438\u2013445","journal-title":"Calcif Tissue Int"},{"key":"933_CR87","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jbspin.2016.05.008","volume":"84","author":"GT Sakellariou","year":"2017","unstructured":"Sakellariou GT, Iliopoulos A, Konsta M, Kenanidis E, Potoupnis M, Tsiridis E, Gavana E, Sayegh FE (2017) Serum levels of Dkk-1, sclerostin and VEGF in patients with ankylosing spondylitis and their association with smoking, and clinical, inflammatory and radiographic parameters. Joint Bone Spine 84:309\u2013315","journal-title":"Joint Bone Spine"},{"key":"933_CR88","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/art.27231","volume":"62","author":"D Daoussis","year":"2010","unstructured":"Daoussis D, Liossis SN, Solomou EE, Tsanaktsi A, Bounia K, Karampetsou M, Yiannopoulos G, Andonopoulos AP (2010) Evidence that Dkk-1 is dysfunctional in ankylosing spondylitis. Arthritis Rheum 62:150\u2013158","journal-title":"Arthritis Rheum"},{"key":"933_CR89","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","volume":"39","author":"K Guly\u00e1s","year":"2020","unstructured":"Guly\u00e1s K, Horv\u00e1th \u00c1, V\u00e9gh E et al (2020) Effects of 1-year anti-TNF-\u03b1 therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39:167\u2013175","journal-title":"Clin Rheumatol"},{"key":"933_CR90","first-page":"146","volume":"39","author":"N Ustun","year":"2014","unstructured":"Ustun N, Tok F, Kalyoncu U, Motor S, Yuksel R, Yagiz AE, Guler H, Turhanoglu AD (2014) Sclerostin and Dkk-1 in patients with ankylosing spondylitis. Acta rReumatol Portuguesa 39:146\u2013151","journal-title":"Acta rReumatol Portuguesa"},{"key":"933_CR91","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/art.24888","volume":"60","author":"H Appel","year":"2009","unstructured":"Appel H, Ruiz-Heiland G, Listing J et al (2009) Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum 60:3257\u20133262","journal-title":"Arthritis Rheum"},{"key":"933_CR92","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2018.03.013","volume":"111","author":"MT Drake","year":"2018","unstructured":"Drake MT, Fenske JS, Blocki FA, Zierold C, Appelman-Dijkstra N, Papapoulos S, Khosla S (2018) Validation of a novel, rapid, high precision sclerostin assay not confounded by sclerostin fragments. Bone 111:36\u201343","journal-title":"Bone"},{"key":"933_CR93","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1080\/08820139.2019.1567531","volume":"48","author":"M Chen","year":"2019","unstructured":"Chen M, Hu X, Wu M et al (2019) Serum levels of OPG, RANKL, and RANKL\/OPG ratio in patients with ankylosing spondylitis: a systematic review and meta-analysis. Immunol Invest 48:490\u2013504","journal-title":"Immunol Invest"},{"key":"933_CR94","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-immunol-032414-112110","volume":"33","author":"P Bowness","year":"2015","unstructured":"Bowness P (2015) HLA-B27. Annu Rev Immunol 33:29\u201348","journal-title":"Annu Rev Immunol"},{"key":"933_CR95","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0009-8981(99)00170-9","volume":"289","author":"C Acebes","year":"1999","unstructured":"Acebes C, de la Piedra C, Traba ML, Seibel MJ, Garc\u00eda Mart\u00edn C, Armas J, Herrero-Beaumont G (1999) Biochemical markers of bone remodeling and bone sialoprotein in ankylosing spondylitis. Clinica Chim Acta 289:99\u2013110","journal-title":"Clinica Chim Acta"},{"key":"933_CR96","first-page":"929","volume":"25","author":"WD Bronson","year":"1998","unstructured":"Bronson WD, Walker SE, Hillman LS, Keisler D, Hoyt T, Allen SH (1998) Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 25:929\u2013935","journal-title":"J Rheumatol"},{"key":"933_CR97","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1007\/s10067-010-1543-y","volume":"29","author":"CH Chen","year":"2010","unstructured":"Chen CH, Chen HA, Liao HT, Liu CH, Tsai CY, Chou CT (2010) Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation. Clin Rheumatol 29:1155\u20131161","journal-title":"Clin Rheumatol"},{"key":"933_CR98","doi-asserted-by":"crossref","first-page":"814350","DOI":"10.1155\/2013\/814350","volume":"2013","author":"V Dhir","year":"2013","unstructured":"Dhir V, Srivastava R, Aggarwal A (2013) Circulating levels of soluble receptor activator of N-\u03ba B ligand and matrix metalloproteinase 3 (and their antagonists) in Asian Indian patients with ankylosing spondylitis. Int J Rheumatol 2013:814350","journal-title":"Int J Rheumatol"},{"key":"933_CR99","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s10067-004-1039-8","volume":"24","author":"A El Maghraoui","year":"2005","unstructured":"El Maghraoui A, Tellal S, Chaouir S, Lebbar K, Bezza A, Nouijai A, Achemlal L, Bouhssain S, el Derouiche M (2005) Bone turnover markers, anterior pituitary and gonadal hormones, and bone mass evaluation using quantitative computed tomography in ankylosing spondylitis. Clin Rheumatol 24:346\u2013351","journal-title":"Clin Rheumatol"},{"key":"933_CR100","first-page":"1430","volume":"29","author":"J Grisar","year":"2002","unstructured":"Grisar J, Bernecker PM, Aringer M et al (2002) Ankylosing spondylitis, psoriatic arthritis, and reactive arthritis show increased bone resorption, but differ with regard to bone formation. J Rheumatol 29:1430\u20131436","journal-title":"J Rheumatol"},{"key":"933_CR101","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.bbrc.2017.11.083","volume":"495","author":"C Hou","year":"2018","unstructured":"Hou C, Luan L, Ren C (2018) Oxidized low-density lipoprotein promotes osteoclast differentiation from CD68 positive mononuclear cells by regulating HMGB1 release. Biochem Biophys Res Commun 495:1356\u20131362","journal-title":"Biochem Biophys Res Commun"},{"key":"933_CR102","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13075-017-1417-7","volume":"19","author":"DR Jadon","year":"2017","unstructured":"Jadon DR, Sengupta R, Nightingale A et al (2017) Serum bone-turnover biomarkers are associated with the occurrence of peripheral and axial arthritis in psoriatic disease: a prospective cross-sectional comparative study. Arthritis Res Ther 19:210","journal-title":"Arthritis Res Ther"},{"key":"933_CR103","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/rheumatology\/kel072","volume":"45","author":"HR Kim","year":"2006","unstructured":"Kim HR, Lee SH, Kim HY (2006) Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS). Rheumatology (Oxford) 45:1197\u20131200","journal-title":"Rheumatology (Oxford)"},{"key":"933_CR104","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1136\/ard.54.7.556","volume":"54","author":"W Marhoffer","year":"1995","unstructured":"Marhoffer W, Stracke H, Masoud I, Scheja M, Graef V, Bolten W, Federlin K (1995) Evidence of impaired cartilage\/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 54:556\u2013559","journal-title":"Ann Rheum Dis"},{"key":"933_CR105","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s10067-010-1648-3","volume":"30","author":"L Muntean","year":"2011","unstructured":"Muntean L, Rojas-Vargas M, Font P, Simon SP, Rednic S, Schiotis R, Stefan S, Tamas MM, Bolosiu HD, Collantes-Est\u00e9vez E (2011) Relative value of the lumbar spine and hip bone mineral density and bone turnover markers in men with ankylosing spondylitis. Clin Rheumatol 30:691\u2013695","journal-title":"Clin Rheumatol"},{"key":"933_CR106","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s12891-017-1425-4","volume":"18","author":"CC Niu","year":"2017","unstructured":"Niu CC, Lin SS, Yuan LJ, Chen LH, Yang CY, Chung AN, Lu ML, Tsai TT, Lai PL, Chen WJ (2017) Correlation of blood bone turnover biomarkers and Wnt signaling antagonists with AS, DISH, OPLL, and OYL. BMC Musculoskelet Disord 18:61","journal-title":"BMC Musculoskelet Disord"},{"key":"933_CR107","doi-asserted-by":"crossref","first-page":"e0144655","DOI":"10.1371\/journal.pone.0144655","volume":"10","author":"IP Perp\u00e9tuo","year":"2015","unstructured":"Perp\u00e9tuo IP, Raposeiro R, Caetano-Lopes J, Vieira-Sousa E, Campanilho-Marques R, Ponte C, Canh\u00e3o H, Ainola M, Fonseca JE (2015) Effect of tumor necrosis factor inhibitor therapy on osteoclasts precursors in ankylosing spondylitis. PLoS ONE 10:e0144655","journal-title":"PLoS ONE"},{"key":"933_CR108","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s10067-016-3198-9","volume":"35","author":"M Serdaro\u011flu Beyazal","year":"2016","unstructured":"Serdaro\u011flu Beyazal M, Erdo\u011fan T, T\u00fcrky\u0131lmaz AK, Devrimsel G, C\u00fcre MC, Beyazal M, Sahin I (2016) Relationship of serum osteoprotegerin with arterial stiffness, preclinical atherosclerosis, and disease activity in patients with ankylosing spondylitis. Clin Rheumatol 35:2235\u20132241","journal-title":"Clin Rheumatol"},{"key":"933_CR109","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s10067-018-4356-z","volume":"38","author":"W Sun","year":"2019","unstructured":"Sun W, Tian L, Jiang L, Zhang S, Zhou M, Zhu J, Xue J (2019) Sclerostin rather than Dickkopf-1 is associated with mSASSS but not with disease activity score in patients with ankylosing spondylitis. Clin Rheumatol 38:989\u2013995","journal-title":"Clin Rheumatol"},{"key":"933_CR110","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1093\/rheumatology\/ken148","volume":"47","author":"D Vosse","year":"2008","unstructured":"Vosse D, Landew\u00e9 R, Garnero P, van der Heijde D, van der Linden S, Geusens P (2008) Association of markers of bone- and cartilage-degradation with radiological changes at baseline and after 2 years follow-up in patients with ankylosing spondylitis. Rheumatology (Oxford) 47:1219\u20131222","journal-title":"Rheumatology (Oxford)"},{"key":"933_CR111","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s100670050024","volume":"19","author":"N Yilmaz","year":"2000","unstructured":"Yilmaz N, Ozaslan J (2000) Biochemical bone turnover markers in patients with ankylosing spondylitis. Clin Rheumatol 19:92\u201398","journal-title":"Clin Rheumatol"},{"key":"933_CR112","first-page":"7870925","volume":"2016","author":"TL Yuan","year":"2016","unstructured":"Yuan TL, Chen J, Tong YL, Zhang Y, Liu YY, Wei JC, Liu Y, Zhao Y, Herrmann M (2016) Serum heme oxygenase-1 and BMP-7 are potential biomarkers for bone metabolism in patients with rheumatoid arthritis and ankylosing spondylitis. Biomed Res Int 2016:7870925","journal-title":"Biomed Res Int"},{"issue":"2","key":"933_CR113","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1097\/BOR.0000000000000475","volume":"30","author":"R Wang","year":"2018","unstructured":"Wang R, Ward MM (2018) Epidemiology of axial spondyloarthritis: an update. Curr Opin Rheumatol 30(2):137\u2013143","journal-title":"Curr Opin Rheumatol"},{"issue":"11","key":"933_CR114","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1136\/annrheumdis-2015-208642","volume":"75","author":"RG Lambert","year":"2016","unstructured":"Lambert RG, Bakker PA, van der Heijde D, Weber U, Rudwaleit M, Hermann KG et al (2016) Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. Ann Rheum Dis 75(11):1958\u20131963","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"933_CR115","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40475","volume":"70","author":"J de Winter","year":"2018","unstructured":"de Winter J, de Hooge M, van de Sande M, de Jong H, van Hoeven L, de Koning A et al (2018) Magnetic resonance imaging of the sacroiliac joints indicating sacroiliitis according to the assessment of spondyloArthritis international society definition in healthy individuals, runners, and women with postpartum back pain. Arthritis Rheumatol 70(7):1042\u20131048","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"933_CR116","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MAJ.0b013e31820f8c59","volume":"341","author":"U Weber","year":"2011","unstructured":"Weber U, Maksymowych WP (2011) Sensitivity and specificity of magnetic resonance imaging for axial spondyloarthritis. Am J Med Sci 341(4):272\u2013277","journal-title":"Am J Med Sci"},{"issue":"8","key":"933_CR117","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1002\/art.20446","volume":"50","author":"AJ Wanders","year":"2004","unstructured":"Wanders AJ, Landewe RB, Spoorenberg A, Dougados M, van der Linden S, Mielants H et al (2004) What is the most appropriate radiologic scoring method for ankylosing spondylitis? A comparison of the available methods based on the outcome measures in rheumatology clinical trials filter. Arthritis Rheum 50(8):2622\u20132632","journal-title":"Arthritis Rheum"},{"issue":"6","key":"933_CR118","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"J Braun","year":"2011","unstructured":"Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E et al (2011) 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896\u2013904","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"933_CR119","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s11926-018-0795-4","volume":"20","author":"I Sari","year":"2018","unstructured":"Sari I, Haroon N (2018) Radiographic progression in ankylosing spondylitis: from prognostication to disease modification. Curr Rheumatol Rep 20(12):82","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"933_CR120","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","volume":"74","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Stolwijk C, van Tubergen A, van der Heijde D, Dougados M, van den Bosch F et al (2015) Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 74(1):52\u201359","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"933_CR121","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1093\/rheumatology\/keu143","volume":"53","author":"A Molto","year":"2014","unstructured":"Molto A, Freire V, Feydy A, Paternotte S, Maksymowych WP, Benhamou M et al (2014) Assessing structural changes in axial spondyloarthritis using a low-dose biplanar imaging system. Rheumatology (Oxford) 53(9):1669\u20131675","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"933_CR122","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1136\/annrheumdis-2017-212553","volume":"77","author":"F de Bruin","year":"2018","unstructured":"de Bruin F, de Koning A, van den Berg R, Baraliakos X, Braun J, Ramiro S et al (2018) Development of the CT Syndesmophyte Score (CTSS) in patients with ankylosing spondylitis: data from the SIAS cohort. Ann Rheum Dis 77(3):371\u2013377","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"933_CR123","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/annrheumdis-2017-211989","volume":"77","author":"A de Koning","year":"2018","unstructured":"de Koning A, de Bruin F, van den Berg R, Ramiro S, Baraliakos X, Braun J et al (2018) Low-dose CT detects more progression of bone formation in comparison to conventional radiography in patients with ankylosing spondylitis: results from the SIAS cohort. Ann Rheum Dis 77(2):293\u2013299","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"933_CR124","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1136\/annrheumdis-2016-210640","volume":"76","author":"T Diekhoff","year":"2017","unstructured":"Diekhoff T, Hermann KG, Greese J, Schwenke C, Poddubnyy D, Hamm B et al (2017) Comparison of MRI with radiography for detecting structural lesions of the sacroiliac joint using CT as standard of reference: results from the SIMACT study. Ann Rheum Dis 76(9):1502\u20131508","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"933_CR125","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1136\/annrheumdis-2018-213393","volume":"77","author":"T Diekhoff","year":"2018","unstructured":"Diekhoff T, Greese J, Sieper J, Poddubnyy D, Hamm B, Hermann KA (2018) Improved detection of erosions in the sacroiliac joints on MRI with volumetric interpolated breath-hold examination (VIBE): results from the SIMACT study. Ann Rheum Dis 77(11):1585\u20131589","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"933_CR126","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.2214\/AJR.17.18636","volume":"210","author":"LS Beltran","year":"2018","unstructured":"Beltran LS, Samim M, Gyftopoulos S, Bruno MT, Petchprapa CN (2018) Does the addition of DWI to fluid-sensitive conventional MRI of the sacroiliac joints improve the diagnosis of sacroiliitis? AJR Am J Roentgenol 210(6):1309\u20131316","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"933_CR127","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1093\/rheumatology\/kex448","volume":"57","author":"STG Bruijnen","year":"2018","unstructured":"Bruijnen STG, Verweij NJF, van Duivenvoorde LM, Bravenboer N, Baeten DLP, van Denderen CJ et al (2018) Bone formation in ankylosing spondylitis during anti-tumour necrosis factor therapy imaged by 18F-fluoride positron emission tomography. Rheumatology (Oxford) 57(4):631\u2013638","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"933_CR128","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00296-017-3660-2","volume":"37","author":"EK Park","year":"2017","unstructured":"Park EK, Pak K, Park JH, Kim K, Kim SJ, Kim IJ et al (2017) Baseline increased 18F-fluoride uptake lesions at vertebral corners on positron emission tomography predict new syndesmophyte development in ankylosing spondylitis: a 2-year longitudinal study. Rheumatol Int 37(5):765\u2013773","journal-title":"Rheumatol Int"},{"issue":"1","key":"933_CR129","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.semarthrit.2017.12.001","volume":"48","author":"J Ramirez","year":"2018","unstructured":"Ramirez J, Nieto-Gonzalez JC, Curbelo Rodriguez R, Castaneda S, Carmona L (2018) Prevalence and risk factors for osteoporosis and fractures in axial spondyloarthritis: a systematic review and meta-analysis. Semin Arthritis Rheum 48(1):44\u201352","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"933_CR130","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1136\/annrheumdis-2012-201845","volume":"72","author":"K Briot","year":"2013","unstructured":"Briot K, Durnez A, Paternotte S, Miceli-Richard C, Dougados M, Roux C (2013) Bone oedema on MRI is highly associated with low bone mineral density in patients with early inflammatory back pain: results from the DESIR cohort. Ann Rheum Dis 72(12):1914\u20131919","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"933_CR131","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nrendo.2010.190","volume":"6","author":"G Schett","year":"2010","unstructured":"Schett G, David JP (2010) The multiple faces of autoimmune-mediated bone loss. Nat Rev Endocrinol 6(12):698\u2013706","journal-title":"Nat Rev Endocrinol"},{"issue":"10","key":"933_CR132","first-page":"1877","volume":"21","author":"C Cooper","year":"1994","unstructured":"Cooper C, Carbone L, Michet CJ, Atkinson EJ, O\u2019Fallon WM, Melton LJ 3rd (1994) Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 21(10):1877\u20131882","journal-title":"J Rheumatol"},{"issue":"12","key":"933_CR133","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1136\/ard.2008.100503","volume":"68","author":"D Vosse","year":"2009","unstructured":"Vosse D, Landewe R, van der Heijde D, van der Linden S, van Staa TP, Geusens P (2009) Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 68(12):1839\u20131842","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"933_CR134","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1002\/jbmr.2217","volume":"29","author":"J Munoz-Ortego","year":"2014","unstructured":"Munoz-Ortego J, Vestergaard P, Rubio JB, Wordsworth P, Judge A, Javaid MK et al (2014) Ankylosing spondylitis is associated with an increased risk of vertebral and nonvertebral clinical fractures: a population-based cohort study. J Bone Miner Res 29(8):1770\u20131776","journal-title":"J Bone Miner Res"},{"issue":"1","key":"933_CR135","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1136\/annrheumdis-2018-213922","volume":"78","author":"J Sahuguet","year":"2019","unstructured":"Sahuguet J, Fechtenbaum J, Molto A, Etcheto A, Lopez-Medina C, Richette P et al (2019) Low incidence of vertebral fractures in early spondyloarthritis: 5-year prospective data of the DESIR cohort. Ann Rheum Dis 78(1):60\u201365","journal-title":"Ann Rheum Dis"},{"key":"933_CR136","doi-asserted-by":"crossref","first-page":"569449","DOI":"10.3389\/fmed.2020.569449","volume":"7","author":"MJ Lim","year":"2020","unstructured":"Lim MJ, Kang KY (2020) A contemporary view of the diagnosis of osteoporosis in patients with axial spondyloarthritis. Front Med (Lausanne). 7:569449","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"933_CR137","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3349\/ymj.2003.44.3.379","volume":"44","author":"K Capaci","year":"2003","unstructured":"Capaci K, Hepguler S, Argin M, Tas I (2003) Bone mineral density in mild and advanced ankylosing spondylitis. Yonsei Med J 44(3):379\u2013384","journal-title":"Yonsei Med J"},{"issue":"2","key":"933_CR138","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/rheumatology\/kev332","volume":"55","author":"K Briot","year":"2016","unstructured":"Briot K, Etcheto A, Miceli-Richard C, Dougados M, Roux C (2016) Bone loss in patients with early inflammatory back pain suggestive of spondyloarthritis: results from the prospective DESIR cohort. Rheumatology (Oxford) 55(2):335\u2013342","journal-title":"Rheumatology (Oxford)"},{"issue":"10","key":"933_CR139","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3899\/jrheum.121417","volume":"40","author":"A Durnez","year":"2013","unstructured":"Durnez A, Paternotte S, Fechtenbaum J, Landewe RB, Dougados M, Roux C et al (2013) Increase in bone density in patients with spondyloarthritis during anti-tumor necrosis factor therapy: 6-year followup study. J Rheumatol 40(10):1712\u20131718","journal-title":"J Rheumatol"},{"issue":"7","key":"933_CR140","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1007\/s00296-012-2632-9","volume":"33","author":"MA Ulu","year":"2013","unstructured":"Ulu MA, Cevik R, Dilek B (2013) Comparison of PA spine, lateral spine, and femoral BMD measurements to determine bone loss in ankylosing spondylitis. Rheumatol Int 33(7):1705\u20131711","journal-title":"Rheumatol Int"},{"issue":"2","key":"933_CR141","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1136\/ard.53.2.117","volume":"53","author":"S Donnelly","year":"1994","unstructured":"Donnelly S, Doyle DV, Denton A, Rolfe I, McCloskey EV, Spector TD (1994) Bone mineral density and vertebral compression fracture rates in ankylosing spondylitis. Ann Rheum Dis 53(2):117\u2013121","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"933_CR142","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1007\/s100670050120","volume":"18","author":"ES Meirelles","year":"1999","unstructured":"Meirelles ES, Borelli A, Camargo OP (1999) Influence of disease activity and chronicity on ankylosing spondylitis bone mass loss. Clin Rheumatol 18(5):364\u2013368","journal-title":"Clin Rheumatol"},{"issue":"3","key":"933_CR143","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3899\/jrheum.170079","volume":"45","author":"KY Kang","year":"2018","unstructured":"Kang KY, Chung MK, Kim HN, Hong YS, Ju JH, Park SH (2018) Severity of sacroiliitis and erythrocyte sedimentation rate are associated with a low trabecular bone score in young male patients with ankylosing spondylitis. J Rheumatol 45(3):349\u2013356","journal-title":"J Rheumatol"},{"issue":"4","key":"933_CR144","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jbspin.2016.05.015","volume":"84","author":"L Wildberger","year":"2017","unstructured":"Wildberger L, Boyadzhieva V, Hans D, Stoilov N, Rashkov R, Aubry-Rozier B (2017) Impact of lumbar syndesmophyte on bone health as assessed by bone density (BMD) and bone texture (TBS) in men with axial spondyloarthritis. Joint Bone Spine 84(4):463\u2013466","journal-title":"Joint Bone Spine"},{"issue":"11","key":"933_CR145","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1136\/annrheumdis-2013-203791","volume":"73","author":"R Kocijan","year":"2014","unstructured":"Kocijan R, Finzel S, Englbrecht M, Engelke K, Rech J, Schett G (2014) Differences in bone structure between rheumatoid arthritis and psoriatic arthritis patients relative to autoantibody positivity. Ann Rheum Dis 73(11):2022\u20132028","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"933_CR146","doi-asserted-by":"crossref","first-page":"R179","DOI":"10.1186\/ar4368","volume":"15","author":"E Klingberg","year":"2013","unstructured":"Klingberg E, Lorentzon M, Gothlin J, Mellstrom D, Geijer M, Ohlsson C et al (2013) Bone microarchitecture in ankylosing spondylitis and the association with bone mineral density, fractures, and syndesmophytes. Arthritis Res Ther 15(6):R179","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"933_CR147","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13075-018-1620-1","volume":"20","author":"A Neumann","year":"2018","unstructured":"Neumann A, Haschka J, Kleyer A, Schuster L, Englbrecht M, Berlin A et al (2018) Cortical bone loss is an early feature of nonradiographic axial spondyloarthritis. Arthritis Res Ther 20(1):202","journal-title":"Arthritis Res Ther"},{"key":"933_CR148","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1136\/annrheumdis-2016-210770","volume":"76","author":"D van der Heijde","year":"2017","unstructured":"van der Heijde D, Ramiro S, Landew\u00e9 R et al (2017) 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 76:978\u2013991","journal-title":"Ann Rheum Dis"},{"key":"933_CR149","doi-asserted-by":"crossref","first-page":"e000396","DOI":"10.1136\/rmdopen-2016-000396","volume":"3","author":"A Sepriano","year":"2017","unstructured":"Sepriano A, Regel A, van der Heijde D et al (2017) Efficacy and safety of biological and targeted-synthetic DMARDs: a systematic literature review informing the 2016 update of the ASAS\/EULAR recommendations for the management of axial spondyloarthritis. RMD Open 3:e000396","journal-title":"RMD Open"},{"key":"933_CR150","first-page":"CD010952","volume":"7","author":"FP Kroon","year":"2015","unstructured":"Kroon FP, van der Burg LR, Ramiro S et al (2015) Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis). Cochrane Database Syst Rev 7:CD010952","journal-title":"Cochrane Database Syst Rev"},{"key":"933_CR151","first-page":"CD005468","volume":"4","author":"LJ Maxwell","year":"2015","unstructured":"Maxwell LJ, Zochling J, Boonen A et al (2015) TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD005468","journal-title":"Cochrane Database Syst Rev"},{"key":"933_CR152","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1080\/1744666X.2019.1561281","volume":"15","author":"S Dubash","year":"2019","unstructured":"Dubash S, Bridgewood C, McGonagle D, Marzo-Ortega H (2019) The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond. Expert Rev Clin Immunol 15:123\u2013134","journal-title":"Expert Rev Clin Immunol"},{"key":"933_CR153","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13075-020-02208-w","volume":"22","author":"Y Yin","year":"2020","unstructured":"Yin Y, Wang M, Liu M et al (2020) Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Res Ther 22:111","journal-title":"Arthritis Res Ther"},{"key":"933_CR154","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1136\/annrheumdis-2011-201252","volume":"71","author":"D Poddubnyy","year":"2012","unstructured":"Poddubnyy D, Rudwaleit M, Haibel H et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71:1616\u20131622","journal-title":"Ann Rheum Dis"},{"key":"933_CR155","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","volume":"65","author":"N Haroon","year":"2013","unstructured":"Haroon N, Inman RD, Learch TJ et al (2013) The impact of tumor necrosis factor \u03b1 inhibitors on radiographic progression in ankylosing spondylitis. Arthritis Rheum 65:2645\u20132654","journal-title":"Arthritis Rheum"},{"key":"933_CR156","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2013-204055","volume":"74","author":"S Ramiro","year":"2015","unstructured":"Ramiro S, Stolwijk C, van Tubergen A et al (2015) Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study. Ann Rheum Dis 74:52\u201359","journal-title":"Ann Rheum Dis"},{"key":"933_CR157","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/art.40661","volume":"71","author":"JW Park","year":"2019","unstructured":"Park JW, Kim MJ, Lee JS et al (2019) Impact of tumor necrosis factor inhibitor versus nonsteroidal antiinflammatory drug treatment on radiographic progression in early ankylosing spondylitis: its relationship to inflammation control during treatment. Arthritis Rheumatol 71:82\u201390","journal-title":"Arthritis Rheumatol"},{"key":"933_CR158","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1093\/rheumatology\/kes364","volume":"52","author":"KY Kang","year":"2013","unstructured":"Kang KY, Ju JH, Park SH, Kim HY (2013) The paradoxical effects of TNF inhibitors on bone mineral density and radiographic progression in patients with ankylosing spondylitis. Rheumatology (Oxford) 52:718\u2013726","journal-title":"Rheumatology (Oxford)"},{"key":"933_CR159","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","volume":"73","author":"X Baraliakos","year":"2014","unstructured":"Baraliakos X, Haibel H, Listing J, Sieper J, Braun J (2014) Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis. Ann Rheum Dis 73:710\u2013715","journal-title":"Ann Rheum Dis"},{"key":"933_CR160","doi-asserted-by":"crossref","first-page":"e0168958","DOI":"10.1371\/journal.pone.0168958","volume":"11","author":"JW Park","year":"2016","unstructured":"Park JW, Kwon HM, Park JK et al (2016) Impact of dose tapering of tumor necrosis factor inhibitor on radiographic progression in ankylosing spondylitis. PLoS ONE 11:e0168958","journal-title":"PLoS ONE"},{"key":"933_CR161","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1136\/annrheumdis-2017-211544","volume":"77","author":"C Molnar","year":"2018","unstructured":"Molnar C, Scherer A, Baraliakos X (2018) TNF blockers inhibit spinal radiographic progression in ankylosing spondylitis by reducing disease activity: results from the Swiss Clinical Quality Management cohort. Ann Rheum Dis 77:63\u201369","journal-title":"Ann Rheum Dis"},{"key":"933_CR162","doi-asserted-by":"publisher","DOI":"10.1002\/art.41667","author":"A Sepriano","year":"2021","unstructured":"Sepriano A, Ramiro S, Wichuk S (2021) TNF inhibitors reduce spinal radiographic progression in patients with radiographic axial spondyloarthritis: a longitudinal analysis from the ALBERTA FORCAST cohort. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.41667","journal-title":"Arthritis Rheumatol"},{"key":"933_CR163","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1136\/ard.2004.033472","volume":"64","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J (2005) Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 64:1462\u20131466","journal-title":"Ann Rheum Dis"},{"key":"933_CR164","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/rheumatology\/kem166","volume":"46","author":"X Baraliakos","year":"2007","unstructured":"Baraliakos X, Listing J, Brandt J (2007) Radiographic progression in patients with ankylosing spondylitis after 4 years of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46:1450\u20131453","journal-title":"Rheumatology (Oxford)"},{"key":"933_CR165","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1002\/art.23901","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Baraliakos X (2008) Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. Arthritis Rheum 58:3063\u20133070","journal-title":"Arthritis Rheum"},{"key":"933_CR166","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.23471","volume":"58","author":"D van der Heijde","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Einstein S (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58:1324\u20131331","journal-title":"Arthritis Rheum"},{"key":"933_CR167","doi-asserted-by":"crossref","first-page":"R127","DOI":"10.1186\/ar2794","volume":"11","author":"D van der Heijde","year":"2009","unstructured":"van der Heijde D, Salonen D, Weissman BN (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 11:R127","journal-title":"Arthritis Res Ther"},{"key":"933_CR168","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s13075-019-1911-1","volume":"21","author":"J Braun","year":"2019","unstructured":"Braun J, Haibel H, de Hooge M (2019) Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison. Arthritis Res Ther 21:142","journal-title":"Arthritis Res Ther"},{"key":"933_CR169","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","volume":"52","author":"A Wanders","year":"2005","unstructured":"Wanders A, Dv H, Landew\u00e9 R (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52:1756\u20131765","journal-title":"Arthritis Rheum"},{"key":"933_CR170","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1136\/annrheumdis-2015-207897","volume":"75","author":"J Sieper","year":"2016","unstructured":"Sieper J, Listing J, Poddubnyy D (2016) Effect of continuous versus on-demand treatment of ankylosing spondylitis with diclofenac over 2 years on radiographic progression of the spine: results from a randomised multicentre trial (ENRADAS). Ann Rheum Dis 75:1438\u20131443","journal-title":"Ann Rheum Dis"},{"key":"933_CR171","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/annrheumdis-2012-203075","volume":"73","author":"J Braun","year":"2014","unstructured":"Braun J, Baraliakos X, Hermann KG (2014) The effect of two golimumab doses on radiographic progression in ankylosing spondylitis: results through 4 years of the GO-RAISE trial. Ann Rheum Dis 73:1107\u20131113","journal-title":"Ann Rheum Dis"},{"key":"933_CR172","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1136\/annrheumdis-2016-209730","volume":"76","author":"J Braun","year":"2017","unstructured":"Braun J, Baraliakos X, Deodhar A (2017) Effect of secukinumab on clinical and radiographic outcomes in ankylosing spondylitis: 2-year results from the randomised phase III MEASURE 1 study. Ann Rheum Dis 76:1070\u20131077","journal-title":"Ann Rheum Dis"},{"key":"933_CR173","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/rheumatology\/key375","volume":"58","author":"J Braun","year":"2019","unstructured":"Braun J, Baraliakos X, Deodhar A (2019) Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study. Rheumatology (Oxford) 58:859\u2013868","journal-title":"Rheumatology (Oxford)"},{"key":"933_CR174","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1002\/art.41164","volume":"72","author":"R Wang","year":"2020","unstructured":"Wang R, Bathon JM, Ward MM (2020) Nonsteroidal antiinflammatory drugs as potential disease-modifying medications in axial spondyloarthritis. Arthritis Rheumatol 72:518\u2013528","journal-title":"Arthritis Rheumatol"},{"key":"933_CR175","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev.biochem.69.1.145","volume":"69","author":"WL Smith","year":"2000","unstructured":"Smith WL, DeWitt DL, Garavito RM (2000) Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 69:145\u2013182","journal-title":"Annu Rev Biochem"},{"key":"933_CR176","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S8756-3282(97)00033-1","volume":"20","author":"M Weinreb","year":"1997","unstructured":"Weinreb M, Suponitzky I, Keila S (1997) Systemic administration of an anabolic dose of PGE2 in young rats increases the osteogenic capacity of bone marrow. Bone 20:521\u2013526","journal-title":"Bone"},{"key":"933_CR177","doi-asserted-by":"crossref","first-page":"e014591","DOI":"10.1136\/bmjopen-2016-014591","volume":"7","author":"F Proft","year":"2017","unstructured":"Proft F, Muche B, Listing J, Rios-Rodriguez V, Sieper J, Poddubnyy D (2017) Study protocol: COmparison of the effect of treatment with Nonsteroidal anti- inflammatory drugs added to anti-tumour necrosis factor a therapy versus anti-tumour necrosis factor a therapy alone on progression of StrUctural damage in the spine over two years in patients with ankyLosing spondylitis (CONSUL)\u2013an open-label randomized controlled multicenter trial. BMJ Open 7:e014591","journal-title":"BMJ Open"},{"key":"933_CR178","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/BOR.0000000000000179","volume":"27","author":"S Tan","year":"2015","unstructured":"Tan S, Wang R, Ward MM et al (2015) Syndesmophyte growth in ankylosing spondylitis. Curr Opin Rheumatol 27:326\u2013332","journal-title":"Curr Opin Rheumatol"},{"key":"933_CR179","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/art.24132","volume":"60","author":"WP Maksymowych","year":"2009","unstructured":"Maksymowych WP, Chiowchanwisawakit P, Clare T, Pedersen SJ, \u00d8stergaard M, Lambert RG (2009) Inflammatory lesions of the spine on magnetic resonance imaging predict the development of new syndesmophytes in ankylosing spondylitis: evidence of a relationship between inflammation and new bone formation. Arthritis Rheum 60:93\u2013102","journal-title":"Arthritis Rheum"},{"key":"933_CR180","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2011-200308","volume":"71","author":"J Braun","year":"2012","unstructured":"Braun J, Baraliakos X, Hermann KG et al (2012) Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis 71:878\u2013884","journal-title":"Ann Rheum Dis"},{"key":"933_CR181","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.10883","volume":"48","author":"J Braun","year":"2003","unstructured":"Braun J, Baraliakos X, Golder W et al (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48:1126\u20131136","journal-title":"Arthritis Rheum"},{"key":"933_CR182","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/art.20977","volume":"52","author":"X Baraliakos","year":"2005","unstructured":"Baraliakos X, Davis J, Tsuji W, Braun J et al (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52:1216\u20131223","journal-title":"Arthritis Rheum"},{"key":"933_CR183","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1002\/art.23044","volume":"56","author":"RG Lambert","year":"2007","unstructured":"Lambert RG, Salonen D, Rahman P et al (2007) Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 56:4005\u20134014","journal-title":"Arthritis Rheum"},{"key":"933_CR184","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jbspin.2015.06.013","volume":"83","author":"JR Zhang","year":"2016","unstructured":"Zhang JR, Liu XJ, Xu WD, Dai SM (2016) Effects of tumor necrosis factor-\u03b1 inhibitors on new bone formation in ankylosing spondylitis. Joint Bone Spine 83:257\u2013264","journal-title":"Joint Bone Spine"},{"key":"933_CR185","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jbspin.2008.04.006","volume":"75","author":"P Claudepierre","year":"2008","unstructured":"Claudepierre P, Wendling D (2008) Are inflammation and ossification on separate tracks in ankylosing spondylitis? Joint Bone Spine 75:520\u2013522","journal-title":"Joint Bone Spine"},{"key":"933_CR186","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.jbspin.2013.02.004","volume":"80","author":"D Wendling","year":"2013","unstructured":"Wendling D, Claudepierre P (2013) New bone formation in axial spondyloarthritis. Joint Bone Spine 80:454\u2013458","journal-title":"Joint Bone Spine"},{"key":"933_CR187","doi-asserted-by":"crossref","first-page":"1759720","DOI":"10.1177\/1759720X20906040","volume":"12","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos X, Gensler LS, D\u2019Angelo S et al (2020) Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: a structured literature review. Ther Adv Musculoskelet Dis 12:1759720","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"933_CR188","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/1756-185X.13270","volume":"21","author":"H Jeong","year":"2018","unstructured":"Jeong H, Eun YH, Kim IY et al (2018) Effect of tumor necrosis factor \u03b1 inhibitors on spinal radiographic progression in patients with ankylosing spondylitis. Int J Rheum Dis 21:1098\u20131105","journal-title":"Int J Rheum Dis"},{"key":"933_CR189","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","volume":"13","author":"G Schett","year":"2017","unstructured":"Schett G, Lories RJ, D\u2019Agostino MA (2017) Enthesitis: from pathophysiology to treatment. Nat Rev Rheumatol 13:731\u2013741","journal-title":"Nat Rev Rheumatol"},{"key":"933_CR190","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41584-018-0091-8","volume":"14","author":"EM Gravallese","year":"2018","unstructured":"Gravallese EM, Schett G (2018) Effects of the IL-23-IL-17 pathway on bone in spondyloarthritis. Nat Rev Rheumatol 14:631\u2013640","journal-title":"Nat Rev Rheumatol"},{"key":"933_CR191","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s40261-020-00886-7","volume":"40","author":"X Baraliakos","year":"2020","unstructured":"Baraliakos X, \u00d8stergaard M, Gensler LS (2020) Comparison of the effects of secukinumab and adalimumab biosimilar on radiographic progression in patients with ankylosing spondylitis: design of a randomized, phase IIIb study (SURPASS). Clin Drug Investig 40:269\u2013278","journal-title":"Clin Drug Investig"},{"key":"933_CR192","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.bone.2011.04.022","volume":"49","author":"RG Russell","year":"2011","unstructured":"Russell RG (2011) Bisphosphonates: the first 40 years. Bone 49:2\u201319","journal-title":"Bone"},{"key":"933_CR193","doi-asserted-by":"crossref","first-page":"115244","DOI":"10.1016\/j.bone.2020.115244","volume":"134","author":"SE Papapoulos","year":"2020","unstructured":"Papapoulos SE (2020) Pamidronate; a model compound of the pharmacology of nitrogen-containing bisphosphonates; a Leiden historical perspective. Bone 134:115244","journal-title":"Bone"},{"key":"933_CR194","doi-asserted-by":"crossref","first-page":"115493","DOI":"10.1016\/j.bone.2020.115493","volume":"139","author":"MJ Rogers","year":"2020","unstructured":"Rogers MJ, M\u00f6nkk\u00f6nen J, Munoz MA (2020) Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Bone 139:115493","journal-title":"Bone"},{"key":"933_CR195","doi-asserted-by":"crossref","first-page":"115887","DOI":"10.1016\/j.bone.2021.115887","volume":"146","author":"P Peris","year":"2021","unstructured":"Peris P, Monegal A, Gua\u00f1abens N (2021) Bisphosphonates in inflammatory rheumatic diseases. Bone 146:115887","journal-title":"Bone"},{"key":"933_CR196","doi-asserted-by":"crossref","first-page":"115512","DOI":"10.1016\/j.bone.2020.115512","volume":"138","author":"A Giusti","year":"2020","unstructured":"Giusti A, Camellino D, Saverino D et al (2020) Zoledronate decreases CTLA-4 in vivo and in vitro independently of its action on bone resorption. Bone 138:115512","journal-title":"Bone"},{"key":"933_CR197","doi-asserted-by":"crossref","first-page":"300","DOI":"10.23736\/S0026-4806.18.05688-4","volume":"109","author":"B Frediani","year":"2018","unstructured":"Frediani B, Giusti A, Bianchi G et al (2018) Clodronate in the management of different musculoskeletal conditions. Minerva Med 109:300\u2013325","journal-title":"Minerva Med"},{"key":"933_CR198","doi-asserted-by":"crossref","first-page":"e000056","DOI":"10.1136\/rmdopen-2015-000056","volume":"1","author":"A Giusti","year":"2015","unstructured":"Giusti A, Bianchi G (2015) Treatment of complex regional pain syndrome type I with bisphosphonates. RMD Open 1:e000056","journal-title":"RMD Open"},{"key":"933_CR199","first-page":"445","volume":"35","author":"L Coates","year":"2017","unstructured":"Coates L, Packham JC, Creamer P et al (2017) Clinical efficacy of oral alendronate in ankylosing spondylitis: a randomised placebo-controlled trial. Clin Exp Rheumatol 35:445\u2013451","journal-title":"Clin Exp Rheumatol"},{"key":"933_CR200","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/03009742.2015.1038300","volume":"44","author":"CC Mok","year":"2015","unstructured":"Mok CC, Li OC, Chan KL, Ho LY, Hui PK (2015) Effect of golimumab and pamidronate on clinical efficacy and MRI inflammation in axial spondyloarthritis: a 48-week open randomized trial. Scand J Rheumatol 44:480\u2013486","journal-title":"Scand J Rheumatol"},{"key":"933_CR201","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/ket321","volume":"53","author":"O Viapiana","year":"2014","unstructured":"Viapiana O, Gatti D, Idolazzi L et al (2014) Bisphosphonates vs infliximab in ankylosing spondylitis treatment. Rheumatology (Oxford) 53:90\u201394","journal-title":"Rheumatology (Oxford)"},{"key":"933_CR202","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.10139","volume":"46","author":"WP Maksymowych","year":"2002","unstructured":"Maksymowych WP, Jhangri GS, Fitzgerald AA et al (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46:766\u2013773","journal-title":"Arthritis Rheum"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00933-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-021-00933-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-021-00933-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T23:09:52Z","timestamp":1700089792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-021-00933-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,23]]},"references-count":202,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["933"],"URL":"https:\/\/doi.org\/10.1007\/s00223-021-00933-1","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,23]]},"assertion":[{"value":"19 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Willem F Lems, speakers fee and advisory boards: Galapagos, Pfizer, Lilly, Amgen, and UCB. Corinne Miceli-Richard: None in relation with this paper. Judith Haschka\u00a0: None in relation with this paper. Andrea Giusti: None in relation with this paper. Gitte Lund Christensen: None in relation with this paper and Roland Kocijan: None in relation with this paper. Nicolas Rosine: None in relation with this paper. Niklas Rye J\u00f8rgensen: None in relation with this paper. Gerolamo Bianchi: None in relation with this paper. Christian Roux: None in relation to this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}